DICE Therapeutics is a biopharmaceutical company using its proprietary technology platform to build a pipeline of oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Co.'s platform, DELSCAPE, is designed to discover selective oral small molecules with the potential to modulate protein-protein interactions. Co.'s therapeutic candidate, DC-806, is an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17, which is a validated drug target implicated in various immunology indications. Co. is also developing oral therapeutic candidates for the treatment of inflammatory bowel disease and idiopathic pulmonary fibrosis, respectively. The DICE average annual return since 2021 is shown above.
The Average Annual Return on the DICE average annual return since 2021 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether DICE average annual return since 2021 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the DICE average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|